Relenza, manufactured by GlaxoSmithKline, contains Laninamivir octanoate hydrate with YJ code 6250702G1028, standardized at 5mg per blister. Relenza (zanamivir) is an antiviral inhalation powder used to treat and prevent influenza A and B virus infections, and should be started within two days of symptom onset for treatment.
Relenza
Need more detailed information?
Contact TASAKI PHARMA for inquiries about this medicine (English support available).
Contact us about this drug →